000			01542cab a2200301Ia 45 0
001			u186857
003			SIRSI
008			101107s2009 ua ss b eng d
040			_aEAL
090			_aART JGEB V7 No2 7
100	1		_aDonya, Souria M.
240	1	0	_aJournal of genetic engineering and biotechnology, 2009.v. 7 (2) _h[electronic resource].
245	1	4	_aThe protective role of folic acid, vitamin B12 and vitamin C on the mutagenicity of the anticancer drug ifosfamide _h[electronic resource].
300			_ap.41-50.
504			_aIncludes references.
520			_aIfosfamide (Holoxan, IFO) is an oxazaphospoorine alkylating agent with a broad spectrum of antineoplastic activity. IFO can damage DNA during any phase of the celI cycle and therefore, is not phase-specific. Thus the objective of this investigation is to measure the potential cytotoxicity of IFO alone and in combination with vitamins (FA, VB12 and VC) The genotoxic potential of IFO was evaluated in vivo using different mutagenic end points.
650		0	_aFolic acid _xPhysiological effect.
650		0	_aVitamin B12 _xPhysiological effect.
650		0	_aVitamin C _xPhysiological effect.
650		0	_aDNA damage.
650		0	_aAntineoplastic agents.
650		0	_aCancer _xTreatment.
700	1		_aAly, Fawzia A.
700	1		_aAbo-Zeid, Mona A. M.
773	0		_tJournal of Genetic Engineering and Biotechnology. _g2009.v.7(2) _x1687-157X _7nnas _wu186667
856	4	0	_uhttp://nile.enal.sci.eg/EALE/2009/JGEB/709/2/41.pdf _zFull Text Article.
596			_a1
942			_cAR _2lcc
999			_c41964 _d41964